What is the dosage of Dupixent?

Dupixent is available in 5 dosages, including 150 mg/ml Auto-Injector 2 ml, 150 mg/ml Prefilled Syringe 0.67 ml, 150 mg/ml Prefilled Syringe 2 ml, 175 mg/ml Auto-Injector 1.14 ml and 175 mg/ml Prefilled Syringe 1.14 ml

What does Dupixent treat?

Dupixent treats Atopic Dermatitis

What is Dupixent made of?

Dupixent contains dupilumab which is a Interleukin-4 Receptor alpha Antagonist

How is Dupixent administered?

Dupixent is administered as a Injectable

What is Dupixent mechanism of action?

Dupixent mechanism of action is Interleukin 4 Receptor alpha Antagonists

Dosage & Administration Drug label Samples Prior authorization Financial assistance

Patient education

Dupixent

(dupilumab)

0.67 ML dupilumab 150 MG/ML Prefilled Syringe [Dupixent]1.14 ML dupilumab 175 MG/ML Auto-Injector [Dupixent]

View 3 more

NO BLACK BOX WARNING

Dosage & administration

Atopic Dermatitis

Dosage in Adults :

* Recommended dosage is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W).

Dosage in Pediatric Patients 6 Months to 5 Years of Age :

Body Weight	Initial and Subsequent Dosage
5 to less than 15 kg	200 mg (one 200 mg injection) every 4 weeks (Q4W)
15 to less than 30 kg	300 mg (one 300 mg injection) every 4 weeks (Q4W)

Dosage in Pediatric Patients 6 Years to 17 Years of Age :

Body Weight	Initial Loading Dose	Subsequent Dosage *
* Q2W – every other week; Q4W – every 4 weeks
15 to less than 30 kg	600 mg (two 300 mg injections)	300 mg Q4W
30 to less than 60 kg	400 mg (two 200 mg injections)	200 mg Q2W
60 kg or more	600 mg (two 300 mg injections)	300 mg Q2W

Asthma

Dosage in Adult and Pediatric Patients 12 Years and Older :

Initial Loading Dose	Subsequent Dosage
400 mg (two 200 mg injections)	200 mg every 2 weeks (Q2W)
or
600 mg (two 300 mg injections)	300 mg every 2 weeks (Q2W)
Dosage for patients with oral corticosteroid-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid chronic rhinosinusitis with nasal polyposis
600 mg (two 300 mg injections)	300 mg every 2 weeks (Q2W)

Dosage in Pediatric Patients 6 to 11 Years of Age :

Body Weight	Initial Dose and Subsequent Dosage
15 to less than 30 kg	100 mg every other week (Q2W) or 300 mg every four weeks (Q4W)
≥30 kg	200 mg every other week (Q2W)

For pediatric patients 6 to 11 years old with asthma and co-morbid moderate-to-severe atopic dermatitis, follow the recommended dosage as per Table 2 which includes an initial loading dose.

Chronic Rhinosinusitis with Nasal Polyposis :

* Recommended dosage for adult patients is 300 mg given every other week (Q2W).

Eosinophilic Esophagitis :

* Recommended dosage for adult and pediatric patients 12 years of age and older, weighing at least 40 kg, is 300 mg given every week (QW).

Prurigo Nodularis :

* Recommended dosage for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W).

drug label

Dupixent prescribing information

Have more Dupixent questions?

Submit MSL Request

Learn More

Need to report a Dupixent issue?

ONLINE FORMReport adverse event

Learn More

samples

Request Dupixent samples

NOT PROVIDED BY BRANDView Online Sample Form

Learn More

prior authorization

Dupixent Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

Coverage Authorization Request

NOT PROVIDED BY BRANDComplete Coverage Authorization appeals

Dupixent MyWay Enrollment Forms - All Indications

Coverage Authorization Appeal

Medical Exception Letter

PA Checklist: Atopic Dermatitis

PA Checklist: Asthma

PA Checklist: Eosinophilic Esophagitis

PA Checklist: Prurigo Nodularis

Learn More

Benefits investigation

Dupixent MyWay Enrollment Forms - All Indications

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Dupixent Financial assistance options

Co-pay savings program

commercial only

Dupixent MyWay Enrollment Forms - All Indications

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Dupixent MyWay Enrollment Forms - All Indications

Bridge Program

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Dupixent MyWay Enrollment Forms - All Indications

Dupixent Patient Assitance Program Eligibility (Through Dupixent MyWay Program )

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement